Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures

Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures

Neil Ghodadra, Kern SinghDepartment of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USAAbstract: Over one million fractures occur per year in the US and are associated with impaired healing increasing patient morbidity, stress, and economic costs. Despite improvements in su...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Neil Ghodadra, Kern Singh
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/9ff22d1c8a5d4d1eb798cea814a54ec3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9ff22d1c8a5d4d1eb798cea814a54ec3
record_format dspace
spelling oai:doaj.org-article:9ff22d1c8a5d4d1eb798cea814a54ec32021-12-02T02:16:53ZRecombinant human bone morphogenetic protein-2 in the treatment of bone fractures1177-54751177-5491https://doaj.org/article/9ff22d1c8a5d4d1eb798cea814a54ec32008-09-01T00:00:00Zhttp://www.dovepress.com/recombinant-human-bone-morphogenetic-protein-2-in-the-treatment-of-bon-a2286https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Neil Ghodadra, Kern SinghDepartment of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USAAbstract: Over one million fractures occur per year in the US and are associated with impaired healing increasing patient morbidity, stress, and economic costs. Despite improvements in surgical technique, internal fixation, and understanding of biologics, fracture healing is delayed or impaired in up to 4% of all fractures. Complications due to impaired fracture healing present therapeutic challenges to the orthopedic surgeon and often lead to chronic functional and psychological disability for the patient. As a result, it has become clinically desirable to augment mechanical fixation with biologic strategies in order to accelerate osteogenesis and promote successful arthrodesis. The discovery of bone morphogenic protein (BMP) has been pivotal in understanding the biology of fracture healing and has been a source of intense clinical research as an adjunct to fracture treatment. Multiple in vitro and in vivo studies in animals have elucidated the complex biologic interactions between BMPs and cellular receptors and have convincingly demonstrated rhBMP-2 to be a safe, effective treatment option to enhance bone healing. Multiple clinical trials in trauma surgery have provided level 1 evidence for the use of rhBMP-2 as a safe and effective treatment of fractures. Human clinical trials have provided further insight into BMP-2 dosage, time course, carriers, and efficacy in fracture healing of tibial defects. These promising results have provided hope that a new biologic field of technology has emerged as a useful adjunct in the treatment of skeletal injuries and conditions.Keywords: bone morphogenic protein-2, bone fracture, bone healing Neil GhodadraKern SinghDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 345-354 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Neil Ghodadra
Kern Singh
Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
description Neil Ghodadra, Kern SinghDepartment of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USAAbstract: Over one million fractures occur per year in the US and are associated with impaired healing increasing patient morbidity, stress, and economic costs. Despite improvements in surgical technique, internal fixation, and understanding of biologics, fracture healing is delayed or impaired in up to 4% of all fractures. Complications due to impaired fracture healing present therapeutic challenges to the orthopedic surgeon and often lead to chronic functional and psychological disability for the patient. As a result, it has become clinically desirable to augment mechanical fixation with biologic strategies in order to accelerate osteogenesis and promote successful arthrodesis. The discovery of bone morphogenic protein (BMP) has been pivotal in understanding the biology of fracture healing and has been a source of intense clinical research as an adjunct to fracture treatment. Multiple in vitro and in vivo studies in animals have elucidated the complex biologic interactions between BMPs and cellular receptors and have convincingly demonstrated rhBMP-2 to be a safe, effective treatment option to enhance bone healing. Multiple clinical trials in trauma surgery have provided level 1 evidence for the use of rhBMP-2 as a safe and effective treatment of fractures. Human clinical trials have provided further insight into BMP-2 dosage, time course, carriers, and efficacy in fracture healing of tibial defects. These promising results have provided hope that a new biologic field of technology has emerged as a useful adjunct in the treatment of skeletal injuries and conditions.Keywords: bone morphogenic protein-2, bone fracture, bone healing
format article
author Neil Ghodadra
Kern Singh
author_facet Neil Ghodadra
Kern Singh
author_sort Neil Ghodadra
title Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
title_short Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
title_full Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
title_fullStr Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
title_full_unstemmed Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
title_sort recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/9ff22d1c8a5d4d1eb798cea814a54ec3
work_keys_str_mv AT neilghodadra recombinanthumanbonemorphogeneticprotein2inthetreatmentofbonefractures
AT kernsingh recombinanthumanbonemorphogeneticprotein2inthetreatmentofbonefractures
_version_ 1718402612195229696

Ejemplares similares